Heart shield for breast cancer patients: new drug may prevent chemo side effect
NCT ID NCT07233499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if the heart drug nebivolol can protect the hearts of women with HER2-positive breast cancer who are receiving trastuzumab, a treatment that can weaken the heart. Researchers will measure heart function and quality of life in 56 participants over several months. The goal is to find a way to prevent heart damage without interfering with cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute- Cairo University- Egypt
RECRUITINGCairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?